Pharmaceuticals, Biotechnology and Life Sciences
Sweden-based pharmaceutical development company focusing on immunological diseases InDex Pharmaceuticals Holding AB has been granted a patent covering 19 compounds from the company’s DIMS platform by the United States Patent and Trademark Office (USPTO).
Said Darwazah, Chairman and Chief Executive Officer of Hikma, said the 2016 was a year in which the company made “significant strategic progress”, reminding about the acquisition of West-Ward Columbus, the largest
OptiBiotix has confirmed today that Per Rehné and Christina Wood have been appointed to the Board of OptiBiotix. The company in January announced naming the new members.
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
Biocept and Catalyst Pharmaceuticals announced a partnership which will provide Biocept’s Target Selector platform to screen patients diagnosed with LEMS for early onset or recurrence of small cell lung cancer (SCLC).
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
The expansion of product lines and enhanced product development are fueling rising revenues and overall growth in the swelling cannabis market despite recent ambiguous reports of direction of the federal impact on the legal marijuana market
Aytu BioScience, Inc., a specialty pharmaceutical company focused on products in the field of urology, today announced the publication of journal article describing the effectiveness …
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.